Your cart is currently empty!
Lung cancer urine test developed after scientists make new breakthrough

Scientists at the University of Cambridge’s Department of Chemical Engineering and Biotechnology, along with the Early Cancer Institute, have made a significant breakthrough in the early detection of lung cancer. They have developed a pioneering urine test that could potentially signal the first signs of lung cancer, allowing for early intervention and treatment.
Currently, a large number of lung cancer cases are diagnosed at later stages, making the disease more challenging to treat effectively. However, with this new urine test, researchers aim to identify lung cancer in its earliest stages, providing patients with a better chance of overcoming the illness.
The test focuses on detecting specific proteins released by senescent cells, also known as “zombie cells,” in the body. These cells, while still alive, are unable to grow and divide, contributing to tissue damage and creating an environment conducive to cancer development. The newly developed test involves an injectable sensor that interacts with these zombie cell proteins, releasing a detectable compound into urine to indicate their presence.
Professor Ljiljana Fruk explained that the test is designed to identify pathological changes in lung tissue that could lead to cancer development before visible symptoms appear. The researchers hope that this non-invasive and cost-effective urine test could serve as a valuable tool for early cancer detection, particularly among high-risk groups or those prone to cancer recurrence.
Funded by Cancer Research UK, the study aims to streamline the testing process, making it accessible to hospital labs worldwide without the need for expensive imaging equipment. The researchers are optimistic about the test’s potential to detect various types of cancer beyond lung cancer, including breast, melanoma, and pancreatic cancer.
As the study progresses to human trials, experts anticipate validating the effectiveness of the test in real-world applications. Dr. Iain Foulkes, Cancer Research UK’s executive director of research and innovation, emphasised the organisation’s ongoing commitment to advancing cancer research to improve patient outcomes and save lives.
Lung cancer remains a prevalent issue in the UK, with around 50,000 new cases diagnosed each year. Despite advancements in cancer treatment, only 10% of lung cancer patients survive for ten years post-diagnosis. Early detection through innovative tests like the urine test developed by the Cambridge researchers could potentially improve survival rates and quality of life for cancer patients.
In conclusion, the development of this groundbreaking urine test for early lung cancer detection represents a significant stride in the fight against cancer. By prioritising early intervention and detection, researchers hope to transform the landscape of cancer treatment and improve outcomes for patients. The ongoing research and innovation in cancer detection underscore the importance of continued investment in scientific advancements to tackle complex diseases effectively.